Cantor Fitzgerald maintains Overweight on ORIC stock
Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...
ORIC Pharmaceuticals shares surge on potential data leak
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid ...
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...
Investing6d
Cantor Fitzgerald maintains Overweight on ORIC shares, sees upside
On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets ranging from ...
Seeking Alpha8d
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data
ORIC Pharmaceuticals' ORIC-533 was promising ... In February last year, analysts at Cantor Fitzgerald noted that the global addressable market for ORC-114 was over $2.5bn, excluding China.
Lutnick chokes up talking about employees killed on 9/11
Cantor Fitzgerald CEO and Commerce Secretary nominee Howard Lutnick became visibly emotional at his confirmation hearing ...
Yahoo Finance6d
PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year ...
Business Insider3d
Expedia price target raised to $210 from $180 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Expedia (EXPE) to $210 from $180 and keeps a Neutral rating on the shares. Expedia’s Q4 results featured bookings and EBITDA that were above ...